OraVerse Side Effects
Generic name: phentolamine
Note: This document contains side effect information about phentolamine. Some of the dosage forms listed on this page may not apply to the brand name OraVerse.
Some side effects of OraVerse may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to phentolamine: injection injectable, injection powder for solution, injection solution
Along with its needed effects, phentolamine (the active ingredient contained in OraVerse) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking phentolamine:Rare
- erection continuing for more than 4 hours, or painful erection
- lumps in the penis
Some side effects of phentolamine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common or rare
- Bruising or bleeding at place of injection
- burning (mild) along penis
- difficulty in ejaculating
- swelling at place of injection
Phentolamine injected into the penis may cause tingling at the tip of the penis. This is no cause for concern.
For Healthcare Professionals
Applies to phentolamine: compounding powder, injectable powder for injection, injectable solution
Cardiovascular side effects have included hypotension due to reduced peripheral vascular resistance. This has been a significant cardiovascular complication of phentolamine (the active ingredient contained in OraVerse) therapy in some cases. Acute and prolonged hypotensive episodes with reflex tachycardia and cardiac arrhythmias have been reported. Overdosage has been characterized primarily by cardiac arrhythmias, tachycardia and severe hypotension or shock.
If severe hypotension develops, prompt elevation of the patient's legs, infusion of IV fluids and/or volume expanders, and, if necessary, an infusion of norepinephrine (titrated to an acceptable blood pressure) is recommended. Epinephrine should not be used since it may cause a paradoxical reduction in BP.
While limited data have shown that phentolamine can attenuate the marked increases in pulmonary artery pressure and vascular resistance associated with exercise in some patients with primary pulmonary hypertension (PPH), its role in this disease is not clear. A single case of severe, worsened pulmonary hypertension has been reported after the administration of phentolamine to a young woman with PPH. Theoretically, the drug was expected to cause pulmonary arterial vasodilation and an improvement of her condition. Apparently, in patients with PPH, the pulmonary vessels become progressively unresponsive to vasodilator therapy. Phentolamine did induce decreased systemic peripheral vascular resistance in this case, which was associated with increased cardiac output, increased pulmonary blood flow, and, because of a constant pulmonary vascular resistance, increased pulmonary artery blood pressure.
Nervous system side effects have included weakness and dizziness. Anxiety, headache, pupillary contraction and visual disturbances are signs of toxicity.
Respiratory system side effects have included nasal stuffiness, probably due to peripheral vasodilation.
Gastrointestinal side effects have included nausea, vomiting, and diarrhea.
Genitourinary side effects among male patients who directly inject the penile cavernous body have included prolonged erections/priapism, fibrous plaque formation, severe local pain, cavernositis, urethritis, ecchymosis with hematoma, gross hematuria, and hematospermia. Urinary incompetence has not been reported, although the drug has been used to successfully treat urinary obstruction due to benign prostatic hypertrophy.
Hepatic side effects have included transient hepatic abnormalities, manifested as elevations in liver function tests, with direct injection of phentolamine (the active ingredient contained in OraVerse) and papaverine in 0.4% to 40% of men with erectile impotence.
Metabolic side effects have included hypoglycemia. This was probably due to stimulation of insulin as a result of alpha-adrenergic blockade.
More OraVerse resources
- OraVerse Consumer Overview
- OraVerse Advanced Consumer (Micromedex) - Includes Dosage Information
- OraVerse Prescribing Information (FDA)
- Phentolamine Prescribing Information (FDA)
- Phentolamine Professional Patient Advice (Wolters Kluwer)
- Phentolamine Mesylate Monograph (AHFS DI)
- Regitine Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.